These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 7483252)

  • 1. Immunization trial of cats with a replication-defective adenovirus type 5 expressing the ENV gene of feline immunodeficiency virus.
    Gonin P; Fournier A; Oualikene W; Moraillon A; Eloit M
    Vet Microbiol; 1995 Aug; 45(4):393-401. PubMed ID: 7483252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FIV vaccine studies. I. Immune response to recombinant FIV env gene products and outcome after challenge infection.
    Lutz H; Hofmann-Lehmann R; Bauer-Pham K; Holznagel E; Tozzini F; Bendinelli M; Reubel G; Aubert A; Davis D; Cox D
    Vet Immunol Immunopathol; 1995 May; 46(1-2):103-13. PubMed ID: 7618250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of gag- and env-specific cytotoxic T lymphocytes in protective immunity to feline immunodeficiency virus.
    Flynn JN; Beatty JA; Cannon CA; Stephens EB; Hosie MJ; Neil JC; Jarrett O
    AIDS Res Hum Retroviruses; 1995 Sep; 11(9):1107-13. PubMed ID: 8554908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection against FIV challenge infection by genetic vaccination using minimalistic DNA constructs for FIV env gene and feline IL-12 expression.
    Boretti FS; Leutenegger CM; Mislin C; Hofmann-Lehmann R; König S; Schroff M; Junghans C; Fehr D; Huettner SW; Habel A; Flynn JN; Aubert A; Pedersen NC; Wittig B; Lutz H
    AIDS; 2000 Aug; 14(12):1749-57. PubMed ID: 10985311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA vaccination using expression vectors carrying FIV structural genes induces immune response against feline immunodeficiency virus.
    Cuisinier AM; Mallet V; Meyer A; Caldora C; Aubert A
    Vaccine; 1997 Jul; 15(10):1085-94. PubMed ID: 9269051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of subunit vaccines against feline immunodeficiency virus infection.
    Verschoor EJ; Willemse MJ; Stam JG; van Vliet AL; Pouwels H; Chalmers SK; Horzinek MC; Sondermeijer PJ; Hesselink W; de Ronde A
    Vaccine; 1996 Mar; 14(4):285-9. PubMed ID: 8744554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-existing immunity to pathogenic Listeria monocytogenes does not prevent induction of immune responses to feline immunodeficiency virus by a novel recombinant Listeria monocytogenes vaccine.
    Stevens R; Lavoy A; Nordone S; Burkhard M; Dean GA
    Vaccine; 2005 Feb; 23(12):1479-90. PubMed ID: 15670884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection against feline immunodeficiency virus using replication defective proviral DNA vaccines with feline interleukin-12 and -18.
    Dunham SP; Flynn JN; Rigby MA; Macdonald J; Bruce J; Cannon C; Golder MC; Hanlon L; Harbour DA; Mackay NA; Spibey N; Jarrett O; Neil JC
    Vaccine; 2002 Feb; 20(11-12):1483-96. PubMed ID: 11858854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines.
    Siebelink KH; Tijhaar E; Huisman RC; Huisman W; de Ronde A; Darby IH; Francis MJ; Rimmelzwaan GF; Osterhaus AD
    J Virol; 1995 Jun; 69(6):3704-11. PubMed ID: 7745719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A neutralizing antibody-inducing peptide of the V3 domain of feline immunodeficiency virus envelope glycoprotein does not induce protective immunity.
    Lombardi S; Garzelli C; Pistello M; Massi C; Matteucci D; Baldinotti F; Cammarota G; da Prato L; Bandecchi P; Tozzini F
    J Virol; 1994 Dec; 68(12):8374-9. PubMed ID: 7966629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement after feline immunodeficiency virus vaccination.
    Hosie MJ; Osborne R; Reid G; Neil JC; Jarrett O
    Vet Immunol Immunopathol; 1992 Dec; 35(1-2):191-7. PubMed ID: 1337397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gag-specific immune enhancement of lentiviral infection after vaccination with an adenoviral vector in an animal model of AIDS.
    Klonjkowski B; Klein D; Galea S; Gavard F; Monteil M; Duarte L; Fournier A; Sayon S; Górna K; Ertl R; Cordonnier N; Sonigo P; Eloit M; Richardson J
    Vaccine; 2009 Feb; 27(6):928-39. PubMed ID: 19070641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization of cats against feline immunodeficiency virus (FIV) infection by using minimalistic immunogenic defined gene expression vector vaccines expressing FIV gp140 alone or with feline interleukin-12 (IL-12), IL-16, or a CpG motif.
    Leutenegger CM; Boretti FS; Mislin CN; Flynn JN; Schroff M; Habel A; Junghans C; Koenig-Merediz SA; Sigrist B; Aubert A; Pedersen NC; Wittig B; Lutz H
    J Virol; 2000 Nov; 74(22):10447-57. PubMed ID: 11044089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy evaluation of prime-boost protocol: canarypoxvirus-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats.
    Tellier MC; Pu R; Pollock D; Vitsky A; Tartaglia J; Paoletti E; Yamamoto JK
    AIDS; 1998 Jan; 12(1):11-8. PubMed ID: 9456250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salmonella typhimurium aroA recombinants and immune-stimulating complexes as vaccine candidates for feline immunodeficiency virus.
    Tijhaar EJ; Huisman W; Huisman RC; Siebelink KH; Karlas JA; de Ronde A; van Herwijnen R; Mooi FR; Osterhaus AD
    J Gen Virol; 1997 Dec; 78 ( Pt 12)():3265-75. PubMed ID: 9400977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Env-expressing autologous T lymphocytes induce neutralizing antibody and afford marked protection against feline immunodeficiency virus.
    Pistello M; Bonci F; Zabogli E; Conti F; Freer G; Maggi F; Stevenson M; Bendinelli M
    J Virol; 2010 Apr; 84(8):3845-56. PubMed ID: 20130057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of virus burden by immunization with feline immunodeficiency virus Env protein.
    Hosie MJ; Dunsford TH; de Ronde A; Willett BJ; Cannon CA; Neil JC; Jarrett O
    Vaccine; 1996 Apr; 14(5):405-11. PubMed ID: 8735552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Env in resistance of feline immunodeficiency virus (FIV)-infected cats to superinfection by a second FIV strain as determined by using a chimeric virus.
    Giannecchini S; Pistello M; Isola P; Matteucci D; Mazzetti P; Freer G; Bendinelli M
    J Virol; 2007 Oct; 81(19):10474-85. PubMed ID: 17634241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Partial protection by vaccination with recombinant feline immunodeficiency virus surface glycoproteins.
    Leutenegger CM; Hofmann-Lehmann R; Holznagel E; Cuisinier AM; Wolfensberger C; Duquesne V; Cronier J; Allenspach K; Aubert A; Ossent P; Lutz H
    AIDS Res Hum Retroviruses; 1998 Feb; 14(3):275-83. PubMed ID: 9491919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization-induced decrease of the CD4+:CD8+ ratio in cats experimentally infected with feline immunodeficiency virus.
    Lehmann R; von Beust B; Niederer E; Condrau MA; Fierz W; Aubert A; Ackley CD; Cooper MD; Tompkins MB; Lutz H
    Vet Immunol Immunopathol; 1992 Dec; 35(1-2):199-214. PubMed ID: 1363009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.